Canada - English - Health Canada

wockhardt uk limited - insulin isophane injection pork - suspension - 100unit - insulin isophane injection pork 100unit - insulins

United States - English - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

United States - English - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; sodium hydroxide; zinc chloride; phenol; hydrochloric acid; glycerol; water for injections; protamine sulfate; metacresol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; phenol; hydrochloric acid; water for injections; metacresol; zinc chloride; protamine sulfate; sodium hydroxide; glycerol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; zinc chloride; protamine sulfate; sodium hydroxide; metacresol; dibasic sodium phosphate dihydrate; water for injections; glycerol; phenol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 50 iu/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate dihydrate; glycerol; metacresol; hydrochloric acid; zinc chloride; sodium hydroxide; phenol; water for injections; protamine sulfate - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 70 iu/ml; insulin, quantity: 30 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; dibasic sodium phosphate dihydrate; hydrochloric acid; glycerol; zinc chloride; sodium hydroxide; metacresol; water for injections; phenol - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 30 iu/ml; insulin, quantity: 70 iu/ml - injection, suspension - excipient ingredients: glycerol; protamine sulfate; phenol; metacresol; hydrochloric acid; dibasic sodium phosphate dihydrate; zinc chloride; water for injections; sodium hydroxide - the treatment of insulin-requiring diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin, quantity: 100 iu/ml - injection, solution - excipient ingredients: metacresol; glycerol; hydrochloric acid; zinc chloride; water for injections; sodium hydroxide - the treatment of insulin-requiring diabetes.